Oss, October, 28th, 2018 – At the Rare Diseases and Orphan Drugs Global Forum, held in Belgrade (Serbia) 1st and 2nd November, Dr. Guido Zaman will present on NTRC’s precision medicine platforms for drug discovery for oncology and neurodegenerative disease. The Rare Diseases and Orphan Drugs Forum will bring together around fifty individuals from charities, patient organizations, investors, companies and academia with the aim to stimulate collaboration and to improve treatment options for rare disease patients. NTRC supports the development of new precision medicines by linking cellular drug response to cancer gene mutations and gene expression. In a recent study, that will be presented at the conference, all protein forty protein kinase inhibitor drugs that have been approved for clinical use in cancer to date were profiled on a panel of 280 biochemical kinase assays at Carna (www.carnabio.com) and on a panel of more than hundred genetically characterized cancer cell lines from diverse tumour tissue origins (NTRC’s Oncolines™ panel). Biochemical cross-reactivities were linked to cellular response biomarkers and signal transduction pathways. New predictive drug response biomarkers were identified for several kinase inhibitors, suggesting potential new indications for approved anti-cancer drugs. At the conference, Dr. Guido Zaman will also present on NTRC’s internal drug discovery project on the tryptophan metabolizing enzyme TDO. Tryptophan and its metabolites formed in the kynurenine pathway play a role in the body’s immune response against cancer cells and in the development of neurodegenerative disorders, such as Parkinson’s disease. In an ongoing study at NTRC, the expression and activity of tryptophan metabolizing enzymes and the levels of tryptophan and metabolites in liquid biopsies from patients are related to disease status and drug response. In this way, patients with an overactive kynurenine pathway can be selected for treatment with IDO1 or TDO inhibitors. NTRC is one of the corporate sponsors of the Rare Diseases and Orphan Drugs Global Forum.
For more information on the conference and registration, follow: https://www.rarebase.co.uk/rare-diseases-and-orphan-drugs-global-forum-2018
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, GeneNominator™, SynergyFinder™ and SynergyScreen™) and target residence time measurements for protein kinases (ResidenceTimer™) on a fee-for-service basis. NTRC has internal drug discovery programs on IDO1 for cancer immunotherapy and TDO for Parkinson’s disease. For more information please visit www.ntrc.nl or contact firstname.lastname@example.org